Multi-organ Metastatic Cancer Research Articles

Abstract 14094: Gender Difference in Covid-19 Test Status and Disease Outcomes in Heart Failure Patients

Introduction: Heart failure is a common health problem in older patients. As part of quality improvement study we analyzed the data of Heart failure patients admitted for COVID-19 infection in Cook County Health, Stroger Academic Hospital between March 19 and May 27, 2020. Hypothesis: 1. To test if all patient admitted for Covid-19 will test positive. 2. To test if there is gender difference in the Heart failure patients affected by Covid-19 pandemic. Methods: Quality improvement clinical research. Results: For the period stated 74 patients with Heart failure were admitted for treatment of Covid-19 viral infection (31% female vs. 69% male), ages 29 to 88 (Mean 61+/-12). From all Heart failure patients admitted for COVID-19 only 42% tested Covid-19 positive (19% female vs. 81% male).Table:1 From all Heart failure patients admitted (74) there were 3 deaths and they were in patients who tested positive for Covid-19. Their medical condition was complicated by severe comorbidity as HIV, multi-organ metastatic cancer, one patient had DNR/DNI status. From the Heart failure patients admitted for Covid-19 symptoms 96% went home with improved health. Conclusions: Our analysis indicates that there is gender difference in magnitude Covid-19 virus affects Heart Failure patients and in their health outcome. This data may be used as base for individualized health care approach.

The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer

Local treatment of metastases by surgical resection or other ablative therapies is technically feasible in an increasing number of patients with multi-organ metastatic cancer. This results in a growing debate on whether patients with extensive disease, that is traditionally deemed unresectable, may benefit from local treatment of metastases when added to standard palliative systemic therapy. For selected patients with oligometastatic colorectal cancer, local treatment of metastases has become the standard of care based on retrospective reports showing long-term survival rates. In addition to systemic therapy, preliminary evidence suggests that patients with extensive metastatic colorectal cancer may also benefit from local treatment. Here, we present the future perspectives based on the available literature on local treatment approaches in colorectal cancer.